BlueSphere Bio Announces IND Clearance of its First in Human Candidate and New Cell Therapy Portfolio for High-Risk Leukemia Patients

Posted: June 4, 2024 at 2:49 am

TCX-101 Clinical Program: TCR T-Cell therapy product candidate (BSB-1001) to be delivered simultaneously with allogeneic stem cell transplant in patients with active disease or high risk of relapse

Read the rest here:
BlueSphere Bio Announces IND Clearance of its First in Human Candidate and New Cell Therapy Portfolio for High-Risk Leukemia Patients

Related Posts